Fierce Biotech
Roche returns to MediLink with promise of $570M near-term payments for another ADC
Roche has got in on the B7-H3 action, agreeing to $570 million in near-term payments to existing partner MediLink Therapeutics for an antibody-drug conjugate targeting the immune checkpoint protein | Roche has got in on the B7-H3 action, agreeing to $570 million in near-term payments to existing pa…
